The 2nd SafeSciMET Master Course on Nonclinical Regulatory Requirements & Guidelines Succesfully Completes Today
24 highly motivated students from the Pharmaceutical Industry (Merck, Almirall, Sanofi, Novartis, Novo Nordisk, Adlego Biomedical, Orion Pharma) and academic institutions completed today the intensive 5-day SafeSciMET training in nonclinical safety sciences and regulations.
Director Per Spindler, Biopeople, says “With this course, the tailoring of the knowledge of professionals involved in the development of innovative drugs on the regulatory requirements and their scientific basis is expected to promote their ability to select, develop and assess the most promising molecules as innovative therapies. The senior academics with significant regulatory experience from e.g. the German Federal Institute for Drug and Medical Devices and the European Medicines Agency are a key feature of this SafeSciMET course”.